Published April 8, 2020
Published April 8, 2020
UB partner company KSL Biomedical has developed diagnostic tests and is moving forward with clinical validation of prognostic tools that could improve patient care during the COVID-19 outbreak.
The company receives support from UB’s Buffalo Institute for Genomics and Data Analytics (BIG), part of Gov. Andrew M. Cuomo’s economic development effort to advance the Buffalo Niagara region as a center for bioinformatics and life sciences research.
KSL has been engaged with the COVID-19 pandemic for months, with its senior management team traveling to China in January 2020 to work on projects there.
“Experience has shown us that we need good information — accurate, high-capacity tests — to manage the COVID-19 outbreak and help people safely return to the workforce. BIG has provided essential resources, positioning KSL to deliver practical solutions in New York State,” says KSL Biomedical CEO Kevin Lawson. “With the right partners, we can take these technologies further and help stem the outbreak wherever it spreads.”
The company first deployed diagnostic technologies in the outbreak in China, and is seeking funding for deployment and scale-up in the U.S. as soon as possible, Lawson says.
KSL Biomedical is conducting regulatory studies in its clinical laboratories to support launch of products and services in the United States and international markets. This includes:
“These tools will increase COVID-19 testing capacity, afford better management of patients, and yield critical data to flatten the curve and aid in the recovery from the pandemic,” Shen says.
The company pitched the technologies to potential investors on April 3 at Innovate to Ventilate, an event hosted by the Business Incubator Association of New York State.
KSL Biomedical has strong ties to UB. In addition to partnering with BIG, the company’s chief medical officer is Lakshmanan Suresh, clinical professor in the Department of Oral Diagnostic Sciences in UB’s School of Dental Medicine.
Funding from BIG enables UB to leverage research expertise and equipment to collaborate with industry partners in Erie County to bring new or expanded medical products to the market and support job growth in Erie County.
KSL is a Western New York-based company advancing translational medicine and improving the delivery of personalized medicine through development of novel genomic- and proteomic-based diagnostics for cancers and immunological diseases. The company has a robust pipeline of proprietary products and services targeting the United States and the rest of the world.